Published:
Sangui BioTech International, Inc. Files Remaining Reports
WITTEN,Germany, September 8 /PRNewswire/ -- On Wednesday, August 27,
2008, Sangui BioTech International, Inc., filed with the SEC its financial
statements on Form 10KSB for the 2007 financial year (ended June 30, 2007) as
well as the quarterly reports on Forms 10QSB for the quarters ended September
30, 2007, December 31, 2007 as well as March 31, 2008. The company is now
current with its SEC filings.
The Board of Directors has set the date for the forthcoming shareholders'
meeting at October 9, 2007 at 11 a.m. Central European Time. It will take
place inWitten,Germany. The preliminary agenda and proxy statement are
available on the corporate website http://www.sanguibiotech.com. All
documents as well as the date of the meeting are subject to SEC approval,
Shareholders will be informed of any changes via the corporate website.
SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTech
International, Inc. (http://www.pinksheets.com: SGBI)
Some of the statements contained in this news release discuss future
expectations, contain projections of results of operation or financial
condition or state other "forward-looking" information. These statements are
subject to known and unknown risks, uncertainties, and other factors that
could cause the actual results to differ materially from those contemplated
by the statements. The forward-looking information is based on various
factors and is derived using numerous assumptions. Important factors that may
cause actual results to differ from projections include, among many others,
the ability of the Company to raise sufficient capital to meet operating
requirements. Words such as "anticipates," "expects," "intends," "plans,"
"believes," "seeks," "estimates," and variations of such words and similar
expressions are intended to identify such forward-looking statements. Unless
required by law, the Company undertakes no obligation to update publicly any
forward-looking statements, whether as a result of new information, future
events or otherwise.
For more information please contact:
Joachim Fleing
Phone: +49-160-741-27-17
Fax: +49-2302-915-191
e-mail: fleing@sangui.de
SOURCE Sangui Bio Tech International Inc.
Copyright © 2009, PRNewswire
Copyright © 2009, NewsBlaze,
Daily NewsTags: ,BIO,HEA,MTC,ERN,Sangui-BioTech-Intern
Search News
Daily News
